Glucocorticoid Receptor Expression Predicts Good Outcome in response to Taxane-Free, Anthracycline-Based Therapy in Triple Negative Breast Cancer

<div>(a) (i) Box and whisker plot showing GR expression in good (RFS &gt; 3 years) and poor (RFS &lt; 3 years) outcome patients from the in-house TNBC dataset. (ii) Kaplan–Meier curve of relapse free survival in the in-house TNBC dataset based on GR gene expression above (high) and below (low) the median. (b) Box and whisker plot showing GR expression in each of the St. Gallen subtypes in the in-house dataset. (c) Box and whisker plots showing GR expression in normal versus cancerous breast tissue in the publicly available datasets: (i) GSE10797 and (ii) GSE9574. 1 (d) Kaplan–Meier curve of relapse free survival of the entire in-house cohort dichotomised based on GR expression above (high) and below (low) the median.</div>

Journal of Oncology

fig1

Figure 1

Figure 1: Glucocorticoid Receptor Expression Predicts Good Outcome in response to Taxane-Free, Anthracycline-Based Therapy in Triple Negative Breast Cancer 

Figure 1 | Glucocorticoid Receptor Expression Predicts Good Outcome in response to Taxane-Free, Anthracycline-Based Therapy in Triple Negative Breast Cancer 